MX370808B - Compuesto novedoso sustituido con quinolina. - Google Patents

Compuesto novedoso sustituido con quinolina.

Info

Publication number
MX370808B
MX370808B MX2016002125A MX2016002125A MX370808B MX 370808 B MX370808 B MX 370808B MX 2016002125 A MX2016002125 A MX 2016002125A MX 2016002125 A MX2016002125 A MX 2016002125A MX 370808 B MX370808 B MX 370808B
Authority
MX
Mexico
Prior art keywords
substituted compound
novel quinoline
egfr
present
inhibiting activity
Prior art date
Application number
MX2016002125A
Other languages
English (en)
Other versions
MX2016002125A (es
Inventor
Katsumasa Nonoshita
Tadashi Shimamura
Takao Uno
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2016002125A publication Critical patent/MX2016002125A/es
Publication of MX370808B publication Critical patent/MX370808B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un objeto que puede lograrse con la presente invención es proporcionar un compuesto novedoso que tiene efectos inhibidores de EGFR y efectos inhibidores del crecimiento celular, así como un medicamento útil para la prevención y/o tratamiento del cáncer basado en los efectos inhibidores de EGFR; la presente invención proporciona un compuesto representado por la fórmula (I) a continuación, o una sal del mismo. (ver Fórmula).
MX2016002125A 2013-08-22 2014-08-22 Compuesto novedoso sustituido con quinolina. MX370808B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013172746 2013-08-22
PCT/JP2014/071951 WO2015025936A1 (ja) 2013-08-22 2014-08-22 新規キノリン置換化合物

Publications (2)

Publication Number Publication Date
MX2016002125A MX2016002125A (es) 2016-06-28
MX370808B true MX370808B (es) 2020-01-07

Family

ID=52483707

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002125A MX370808B (es) 2013-08-22 2014-08-22 Compuesto novedoso sustituido con quinolina.

Country Status (21)

Country Link
US (2) US9650386B2 (es)
EP (1) EP3037424B1 (es)
JP (1) JP6161705B2 (es)
KR (1) KR101906688B1 (es)
CN (1) CN105683195B (es)
AU (1) AU2014309788B2 (es)
BR (1) BR112016003247B1 (es)
CA (1) CA2922077C (es)
DK (1) DK3037424T3 (es)
ES (1) ES2656712T3 (es)
HU (1) HUE034807T2 (es)
MX (1) MX370808B (es)
MY (1) MY182891A (es)
NO (1) NO3037424T3 (es)
PH (1) PH12016500225A1 (es)
PL (1) PL3037424T3 (es)
PT (1) PT3037424T (es)
RU (1) RU2689158C2 (es)
SG (1) SG11201600759XA (es)
TW (1) TWI603971B (es)
WO (1) WO2015025936A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037424B1 (en) * 2013-08-22 2017-11-08 Taiho Pharmaceutical Co., Ltd. Novel quinoline-substituted compound
JOP20190073A1 (ar) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
US11446302B2 (en) * 2016-11-17 2022-09-20 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
FR3068971B1 (fr) * 2017-07-12 2019-08-30 Protneteomix Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer
JP7065103B2 (ja) * 2017-09-01 2022-05-11 大鵬薬品工業株式会社 エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤
ES3033635T3 (en) * 2018-12-28 2025-08-06 Taiho Pharmaceutical Co Ltd L718 and/or l792 mutant treatment-resistant egfr inhibitor for use in the treatment of cancer
EP3943491B1 (en) 2019-03-19 2025-06-18 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
CN112574208B (zh) * 2019-09-29 2022-09-13 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
CN113861195B (zh) * 2020-06-30 2022-11-18 上海和誉生物医药科技有限公司 一种多稠环egfr抑制剂及其制备方法和应用
WO2022007841A1 (zh) * 2020-07-09 2022-01-13 上海和誉生物医药科技有限公司 一种egfr抑制剂、其制备方法和在药学上的应用
US20230372346A1 (en) * 2020-09-08 2023-11-23 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
JP2024523861A (ja) 2021-06-15 2024-07-02 ジェネンテック， インコーポレイテッド がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用
CN115707704B (zh) * 2021-08-20 2024-09-13 广东医诺维申生物技术有限公司 氘代稠合三环类化合物及其组合物和用途
CN120641417A (zh) 2022-12-08 2025-09-12 亚细亚化学工业有限公司 齐帕勒替尼的固态形式及其制备方法
CN115785107B (zh) * 2022-12-15 2024-11-12 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
JPWO2024248083A1 (es) * 2023-05-31 2024-12-05
WO2025141465A1 (en) 2023-12-27 2025-07-03 Assia Chemical Industries Ltd. Solid state forms of zipalertinib hydrochloride and process for preparation thereof
WO2025167588A1 (zh) * 2024-02-05 2025-08-14 苏州科睿思制药有限公司 Zipalertinib的晶型及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW440562B (en) * 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
RU2007138264A (ru) 2005-03-17 2009-09-10 Новартис АГ (CH) N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF
EP2452940B1 (en) * 2009-07-10 2014-12-17 Taiho Pharmaceutical Co., Ltd. Azabicyclo compound and salt thereof
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2662357B1 (en) * 2011-01-07 2016-08-03 Taiho Pharmaceutical Co., Ltd. Bicyclic compounds or salts thereof for use in the treatment of cancer
US9145414B2 (en) 2011-09-30 2015-09-29 Taiho Pharmaceutical Co., Ltd. 1,2,4-triazine-6-carboxamide derivative
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
WO2013118817A1 (ja) * 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
RU2581039C1 (ru) * 2012-02-23 2016-04-10 Тайхо Фармасьютикал Ко., Лтд. Хинолилпирролпиримидильное конденсированное соединение или его соль
WO2014129596A1 (ja) 2013-02-22 2014-08-28 大鵬薬品工業株式会社 三環性化合物の製造方法及び当該製造方法により得ることができる三環性化合物
EP3037424B1 (en) * 2013-08-22 2017-11-08 Taiho Pharmaceutical Co., Ltd. Novel quinoline-substituted compound

Also Published As

Publication number Publication date
US20170101414A1 (en) 2017-04-13
JPWO2015025936A1 (ja) 2017-03-02
EP3037424A1 (en) 2016-06-29
US9758526B2 (en) 2017-09-12
PL3037424T3 (pl) 2018-03-30
RU2016110096A3 (es) 2018-06-18
JP6161705B2 (ja) 2017-07-12
PH12016500225B1 (en) 2016-05-02
ES2656712T3 (es) 2018-02-28
EP3037424B1 (en) 2017-11-08
CN105683195A (zh) 2016-06-15
PH12016500225A1 (en) 2016-05-02
WO2015025936A1 (ja) 2015-02-26
RU2019114688A (ru) 2020-07-29
EP3037424A4 (en) 2017-01-25
KR20160043114A (ko) 2016-04-20
RU2016110096A (ru) 2017-09-27
HUE034807T2 (en) 2018-02-28
HK1222393A1 (zh) 2017-06-30
KR101906688B1 (ko) 2018-10-10
CN105683195B (zh) 2017-11-10
MX2016002125A (es) 2016-06-28
CA2922077C (en) 2018-06-26
BR112016003247B1 (pt) 2022-05-10
US20160194332A1 (en) 2016-07-07
US9650386B2 (en) 2017-05-16
TWI603971B (zh) 2017-11-01
RU2689158C2 (ru) 2019-05-24
AU2014309788B2 (en) 2017-02-16
PT3037424T (pt) 2017-12-18
MY182891A (en) 2021-02-05
BR112016003247A2 (es) 2017-08-01
CA2922077A1 (en) 2015-02-26
TW201542547A (zh) 2015-11-16
SG11201600759XA (en) 2016-03-30
AU2014309788A1 (en) 2016-03-10
DK3037424T3 (en) 2017-12-11
NO3037424T3 (es) 2018-04-07

Similar Documents

Publication Publication Date Title
PH12016500225A1 (en) Novel quinoline-substituted compound
PH12017501817B1 (en) Heterocyclic compounds as lsd1 inhibitors
TN2015000516A1 (en) Chemical compounds
MA40076A (fr) Inhibiteurs de syk
IN2015DN01156A (es)
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
JO3131B1 (ar) مركبات كيميائية
EA201590661A1 (ru) Азахиназолиновые ингибиторы атипичной протеинкиназы c
PH12012502138B1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
IN2014MN02459A (es)
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
MX362550B (es) Inhibidores ciclicos de glutaminasa.
GEAP201814401A (en) Heterocyclic compounds and their use as retinoidrelated orphan receptor (ror) gamma-t inhibitors
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
PH12016500003A1 (en) Compounds and compositions as inhibitors of mek
WO2014031933A3 (en) Heterocyclic modulators of hif activity for treatment of disease
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
WO2014031936A3 (en) Heterocyclic modulators of hif activity for treatment of disease
IN2015DN01151A (es)
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX349548B (es) Compuestos de tienopirimidina.
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
MX2016004967A (es) Tratamiento para cancer pancreatico.
MX2014007364A (es) Nuevas carboxamidas heterociclicas como modulares de la activadad de cinasas.

Legal Events

Date Code Title Description
FG Grant or registration